2021 CMSC Annual Meeting

Tag: MO

Poster-Symptom Management

Sources of Cannabis Information and Medical Guidance Among People with Multiple Sclerosis: Narcoms Survey Results

Background: The North American Research Committee on Multiple Sclerosis (NARCOMS) registry is a voluntary, self-report registry for people...

Read More

Poster-Self-care

Summary of Diet Intervention Studies in Multiple Sclerosis from the National MS Society Nutrition Wellness Subgroup

Background: Increasing evidence suggests that lifestyle factors such as dietary patterns and exercise impact the risk and course of...

Read More

Poster-Quality of Life and Outcomes

Improving Communication about Multiple Sclerosis: The MS-Support Decision Aid

Background: Good communication between patients and their health care provider (HCP) is essential for shared decision making (SDM). We...

Read More

Poster-Programs

Knowledge, Skills, and Confidence of Healthcare Professionals Participating in the Echo MS Program

Background: ECHO MS is a videoconference-based education and case-consultation program that seeks to expand MS expertise. In Fall 2020, the...

Read More

Poster-Neuroimmunology and disease models

Mucosal Associated Invariant T (MAIT) Cells Show Defective Activation in People with Multiple Sclerosis

Background: mucosal associated invariant T (MAIT) cells are innate-like T cells expressing an invariant TCR ? chain with a limited number...

Read More

Poster-Disease-modifying Therapy

Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...

Read More

Poster-Disease-modifying Therapy

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...

Read More

Poster-Disease-modifying Therapy

Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders

Background: Depletion of B lymphocytes is a known therapeutic strategy for multiple sclerosis (MS) and related disorders. Ocrelizumab (OCR)...

Read More

Poster-Case Reports / Case Series

Case Report of a Severe Cutaneous Lupus Erythematosus Flare in a Patient Treated with Eculizumab for the Treatment of Neuromyeltis Optica Spectrum Disorder

Background:: Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. By preventing the cleavage of C5...

Read More

Poster-Complementary and Alternative Therapies

Mindfulness Based Art Therapy to Improve Symptoms Among Adults with Multiple Sclerosis

Background: Multiple sclerosis (MS) MS affects nearly one million people in the United States and more than two million worldwide. Symptoms...

Read More